<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.infectagentscancer.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Infectious Agents and Cancer - Most accessed articles</title>
        <link>http://www.infectagentscancer.com</link>
        <description>The most accessed research articles published by Infectious Agents and Cancer</description>
        <dc:date>2010-02-12T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/5/1/4" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/5/1/5" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/4/1/16" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/5/1/2" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/4/1/12" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/5/1/3" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/2/1/11" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/5/1/1" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/4/1/14" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/4/1/13" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.infectagentscancer.com/content/5/1/4">
        <title>Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer</title>
        <description>Background:
P16 and p53 protein expression, and high-risk human papillomavirus (HPV-HR) types have been associated with survival in head and neck cancer (HNC). Evidence suggests that multiple molecular pathways need to be targeted to improve the poor prognosis of HNC. This study examined the individual and joint effects of tumor markers for differences in predicting HNC survival. P16 and p53 expression were detected from formalin-fixed, paraffin-embedded tissues by immunohistochemical staining. HPV DNA was detected by PCR and DNA sequencing in 237 histologically confirmed HNC patients.
Results:
Overexpression of p16 (p16+) and p53 (p53+) occurred in 38% and 48% of HNC tumors, respectively. HPV-HR was detected in 28% of tumors. Worse prognosis was found in tumors that were p53+ (disease-specific mortality: adjusted hazard ratios, HR = 1.9, 95% CI: 1.04-3.4) or HPV- (overall survival: adj. HR = 2.1, 1.1-4.3) but no association in survival was found by p16 status. Compared to the molecular marker group with the best prognosis (p16+/p53-/HPV-HR: referent), the p16-/p53+/HPV- group had the lowest overall survival (84% vs. 60%, p &lt; 0.01; HR = 4.1, 1.7-9.9) and disease-specific survival (86% vs. 66%, p &lt; 0.01; HR = 4.0, 1.5-10.7). Compared to the referent, the HRs of the other six joint biomarker groups ranged from 1.6-3.4 for overall mortality and 0.9-3.9 for disease-specific mortality.
Conclusion:
The p16/p53/HPV joint groups showed greater distinction in clinical outcomes compared to results based on the individual biomarkers alone. This finding suggests that assessing multiple molecular markers in HNC patients will better predict the diverse outcomes and potentially the type of treatment targeted to those markers.</description>
        <link>http://www.infectagentscancer.com/content/5/1/4</link>
                <dc:creator>Elaine Smith</dc:creator>
                <dc:creator>Linda Rubenstein</dc:creator>
                <dc:creator>Henry Hoffman</dc:creator>
                <dc:creator>Thomas Haugen</dc:creator>
                <dc:creator>Lubomir Turek</dc:creator>
                <dc:source>Infectious Agents and Cancer 2010, 5:4</dc:source>
        <dc:date>2010-02-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-5-4</dc:identifier>
        <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2010-02-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/5/1/5">
        <title>Impact of infection with human immunodeficiency virus-1 (HIV) on the risk of cancer among children in Malawi - preliminary findings</title>
        <description>Background:
The impact of infection with HIV on the risk of cancer in children is uncertain, particularly for those living in sub-Saharan Africa. In an ongoing study in a paediatric oncology centre in Malawi, children (aged &#8804; 15 years) with known or suspected cancers are being recruited and tested for HIV and their mothers or carers interviewed. This study reports findings for children recruited between 2005 and 2008.
Methods:
Only children with a cancer diagnosis were included. Odds ratios (OR) for being HIV positive were estimated for each cancer type (with adjustment for age (&lt;5 years, &#8805; 5 years) and sex) using children with other cancers and non-malignant conditions as a comparison group (excluding the known HIV-associated cancers, Kaposi sarcoma and lymphomas, as well as children with other haematological malignancies or with confirmed non-cancer diagnoses).
Results:
Of the 586 children recruited, 541 (92%) met the inclusion criteria and 525 (97%) were tested for HIV. Overall HIV seroprevalence was 10%. Infection with HIV was associated with Kaposi sarcoma (29 cases; OR = 93.5, 95% CI 26.9 to 324.4) and with non-Burkitt, non-Hodgkin lymphoma (33 cases; OR = 4.4, 95% CI 1.1 to 17.9) but not with Burkitt lymphoma (269 cases; OR = 2.2, 95% CI 0.8 to 6.4).
Conclusions:
In this study, only Kaposi sarcoma and non-Burkitt, non-Hodgkin lymphoma were associated with HIV infection. The endemic form of Burkitt lymphoma, which is relatively frequent in Malawi, was not significantly associated with HIV. While the relatively small numbers of children with other cancers, together with possible limitations of diagnostic testing may limit our conclusions, the findings may suggest differences in the pathogenesis of HIV-related malignancies in different parts of the world.</description>
        <link>http://www.infectagentscancer.com/content/5/1/5</link>
                <dc:creator>Nora Mutalima</dc:creator>
                <dc:creator>Elizabeth Molyneux</dc:creator>
                <dc:creator>William Johnston</dc:creator>
                <dc:creator>Harold Jaffe</dc:creator>
                <dc:creator>Steve Kamiza</dc:creator>
                <dc:creator>Eric Borgstein</dc:creator>
                <dc:creator>Nyengo Mkandawire</dc:creator>
                <dc:creator>George Liomba</dc:creator>
                <dc:creator>Mkume Batumba</dc:creator>
                <dc:creator>Lucy Carpenter</dc:creator>
                <dc:creator>Robert Newton</dc:creator>
                <dc:source>Infectious Agents and Cancer 2010, 5:5</dc:source>
        <dc:date>2010-02-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-5-5</dc:identifier>
        <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2010-02-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/4/1/16">
        <title>Epithelial maturation and molecular biology of oral HPV</title>
        <description>Human papillomavirus (HPV) is widespread and can cause latent infection in basal cells, with low HPV DNA copy-number insufficient for transmission of infection; can cause subclinical infection that is active but without clinical signs; or can cause clinical infection leading to benign, potentially malignant or malignant lesions. The HPV cycle is influenced by the stage of maturation of the infected keratinocytes, and the production of virions is restricted to the post-mitotic suprabasal epithelial cells where all the virus genes are expressed.Low-risk HPV genotypes are associated with the development of benign oral lesions, whereas high-risk HPV genotypes are implicated in the development of malignant epithelial neoplasms. The r&#244;le of high-risk HPV as a causative agent in epithelial malignancy is different at different anatomical sites: it is almost invariably implicated in squamous cell carcinoma of the uterine cervix, fairly frequently implicated in squamous cell carcinoma of the oropharynx, and it is seldom implicated in squamous cell carcinoma of the mouth.</description>
        <link>http://www.infectagentscancer.com/content/4/1/16</link>
                <dc:creator>Liviu Feller</dc:creator>
                <dc:creator>Razia Khammissa</dc:creator>
                <dc:creator>Neil Wood</dc:creator>
                <dc:creator>Johan Lemmer</dc:creator>
                <dc:source>Infectious Agents and Cancer 2009, 4:16</dc:source>
        <dc:date>2009-11-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-4-16</dc:identifier>
        <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2009-11-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/5/1/2">
        <title>Rapid, Sensitive Type Specific PCR Detection of the E6 and E7 regions of Human Papillomavirus Type 16 and 18 from Paraffin Embedded Sections of Cervical Carcinoma </title>
        <description>Human papillomavirus (HPV) infection, and in particularly infection with HPVs 16 and 18, is a central carcinogenic factor in the uterine cervix. We established and optimized a PCR assay for the detection and discrimination of HPV types 16 and 18 in archival formaldehyde fixed and paraffin embedded (FFPE) sections of cervical cancer.Tissue blocks from 35 cases of in situ or invasive cervical squamous cell carcinoma and surrogate FFPE sections containing the cell lines HeLa and SiHa were tested for HPV 16 and HPV18 by conventional PCR using type specific primers, and for the housekeeping gene &#946;-actin. Using HPV 16 E7 primers, PCR products with the expected length were detected in 18 of 35 of FFPE sections (51%). HPV 18 E7 specific sequences were detected in 3 of 35 FFPE sections (9%).In our experience, the PCR technique is a robust, simple and sensitive way of type specific detection of HPV16 and HPV18 genes in FFPE tissue. That makes this technique applicable to routine practices of HPV detection.</description>
        <link>http://www.infectagentscancer.com/content/5/1/2</link>
                <dc:creator>Iana Lesnikova</dc:creator>
                <dc:creator>Marianne Lidang</dc:creator>
                <dc:creator>Stephen Hamilton-Dutoid</dc:creator>
                <dc:creator>Jorn Koch</dc:creator>
                <dc:source>Infectious Agents and Cancer 2010, 5:2</dc:source>
        <dc:date>2010-01-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-5-2</dc:identifier>
        <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2010-01-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/4/1/12">
        <title>No evidence for WU polyomavirus infection in chronic obstructive pulmonary disease</title>
        <description>Human polyomaviruses are known to cause persistent or latent infections, which are reactivated under immunosuppression. Polyomaviruses have been found to immortalize cell lines and to possess oncogenic properties. Moreover, the recently discovered Merkel cell polyomavirus shows a strong association with human Merkel cell carcinomas. Another novel human polyomavirus, WU polyomavirus (WUPyV), has been identified in respiratory specimens from patients with acute respiratory tract infections (ARTI). WUPyV has been proposed to be a pathogen in ARTI in early life and immunocompromised individuals, but so far its role as a causative agent of respiratory disease remains controversial.The objective of our study was to determine the prevalence of WUPyV infections in adult hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) and to establish its potential clinical relevance by comparison to patients with stable COPD hospitalized for other reasons than acute exacerbation of COPD (AE-COPD).A total of 378 respiratory specimens, each 189 induced sputum and nasal lavage samples from 189 patients, who had been recruited in a prospective 2:1 ratio case-control set-up between 1999 and 2003, were evaluated for the presence of WUPyV DNA by real-time PCR.In the present study we could not detect WUPyV DNA in 378 respiratory specimens from 189 adult hospitalized patients with AE-COPD and stable COPD in four consecutive years.Persistence of viral replication or reactivation of latent WUPyV infection did not occur. WUPyV may not play a major role in adult immunocompetent patients with AE-COPD and stable COPD.</description>
        <link>http://www.infectagentscancer.com/content/4/1/12</link>
                <dc:creator>Felix Ringshausen</dc:creator>
                <dc:creator>Marei Heckmann</dc:creator>
                <dc:creator>Benedikt Weissbrich</dc:creator>
                <dc:creator>Florian Neske</dc:creator>
                <dc:creator>Irmgard Borg</dc:creator>
                <dc:creator>Umut Knoop</dc:creator>
                <dc:creator>Juliane Kronsbein</dc:creator>
                <dc:creator>Barbara Hauptmeier</dc:creator>
                <dc:creator>Gerhard Schultze-Werninghaus</dc:creator>
                <dc:creator>Gernot Rohde</dc:creator>
                <dc:source>Infectious Agents and Cancer 2009, 4:12</dc:source>
        <dc:date>2009-08-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-4-12</dc:identifier>
        <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2009-08-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/5/1/3">
        <title>Bacteria under SOS evolve anticancer phenotypes</title>
        <description>Background:
The anticancer drugs, such as DNA replication inhibitors, stimulate bacterial adhesion and induce the bacterial SOS response. As a variety of bacterial mutants can be generated during SOS, novel phenotypes are likely to be selected under the drug pressure.Presentation of the hypothesisBacteria growing with cancer cells in the presence of the replication inhibitors undergo the SOS response and evolve advantageous phenotypes for the bacteria to invade the cancer cells in order to evade the drug attack. This hypothesis predicts that bacteria produce the proteins that mediate bacterial capture and invasion of cancer cells--the advantageous phenotypes. Generation of the phenotypes may be facilitated during the SOS response induced by anticancer drugs.Testing the hypothesisExperimental design: 1) Examine attachment and invasion of bacterium Pseudomonas aeruginosa and the SOS mutant control to cancer cells in the presence of the anticancer drugs that inhibit DNA replication enzymes and trigger the SOS response. 2) Reveal the bacterial proteins that exhibit changes in expression. 3) Identify the genes encoding cancer adhesion and invasion. 4) Construct the mutants for the genes, clone and express these genes. 5) Examine the bacterial capture and invasion of cancer cells in contrast to non-cancer control.Expected results: 1) The bacterial proteins will be differentially induced during bacteria-cancer interaction under the SOS response to the anticancer drugs. 2) Knocking out the bacterial cancer-adhesion-invasion genes will disrupt the adhesion-invasion phenotypes of the bacteria. 3) Expressing these genes will direct the bacterial capture and invasion of cancer cells.Implications of the hypothesisBacteria can evolve anticancer phenotypes targeting metastatic cells. If this hypothesis is true, the outcomes will contribute to development of a novel bacterial anti-metastasis regimen.</description>
        <link>http://www.infectagentscancer.com/content/5/1/3</link>
                <dc:creator>Shatha Dallo</dc:creator>
                <dc:creator>Tao Weitao</dc:creator>
                <dc:source>Infectious Agents and Cancer 2010, 5:3</dc:source>
        <dc:date>2010-02-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-5-3</dc:identifier>
        <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2010-02-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/2/1/11">
        <title>Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories</title>
        <description>Background:
Human papillomavirus (HPV) genotyping is important for following up patients with persistent HPV infection and for evaluation of prevention strategy for the individual patients to be immunized with type-specific HPV vaccines. The aim of this study was to optimize a robust &quot;low-temperature&quot; (LoTemp&#8482;) PCR system to streamline the research protocols for HPV DNA nested PCR-amplification followed by genotyping with direct DNA sequencing. The protocol optimization facilitates transferring this molecular technology into clinical laboratory practice. In particular, lowering the temperature by 10&#176;C at each step of thermocycling during in vitro DNA amplification yields more homogeneous PCR products. With this protocol, template purification before enzymatic cycle primer extensions is no longer necessary.
Results:
The HPV genomic DNA extracted from liquid-based alcohol-preserved cervicovaginal cells was first amplified by the consensus MY09/MY11 primer pair followed by nested PCR with GP5+/GP6+ primers. The 150 bp nested PCR products were subjected to direct DNA sequencing. The hypervariable 34&#8211;50 bp DNA sequence downstream of the GP5+ primer site was compared to the known HPV DNA sequences stored in the GenBank using on-line BLAST for genotyping. The LoTemp&#8482; ready-to-use PCR polymerase reagents proved to be stable at room temperature for at least 6 weeks. Nested PCR detected 107 isolates of HPV in 513 cervicovaginal clinical samples, all validated by DNA sequencing. HPV-16 was the most prevalent genotype constituting 29 of 107 positive cases (27.2%), followed by HPV-56 (8.5%). For comparison, Digene HC2 test detected 62.6% of the 107 HPV isolates and returned 11 (37.9%) of the 29 HPV-16 positive cases as &quot;positive for high-risk HPV&quot;.
Conclusion:
The LoTemp&#8482; ready-to-use PCR polymerase system which allows thermocycling at 85&#176;C for denaturing, 40&#176;C for annealing and 65&#176;C for primer extension can be adapted for target HPV DNA amplification by nested PCR and for preparation of clinical materials for genotyping by direct DNA sequencing. HPV genotyping is performed by on-line BLAST algorithm of a hypervariable L1 region. The DNA sequence is included in each report to the physician for comparison in following up patients with persistent HPV infection, a recognized tumor promoter in cancer induction.</description>
        <link>http://www.infectagentscancer.com/content/2/1/11</link>
                <dc:creator>Sin Hang Lee</dc:creator>
                <dc:creator>Veronica Vigliotti</dc:creator>
                <dc:creator>Jessica Vigliotti</dc:creator>
                <dc:creator>Suri Pappu</dc:creator>
                <dc:source>Infectious Agents and Cancer 2007, 2:11</dc:source>
        <dc:date>2007-06-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-2-11</dc:identifier>
        <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2007-06-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/5/1/1">
        <title>Association of LEC and tnpA Helicobacter pylori genes with gastric cancer in a Brazilian population</title>
        <description>Background:
H. pylori seroprevalence in Brazilians varies and is dependent on socioeconomic status, sanitation conditions and ethnicity; furthermore, H. pylori is not always associated with the incidence of gastric cancer, suggesting the role of more virulent strains. The purpose of this study was to analyze the association of more virulent H. pylori strains with gastric cancer.
Methods:
DNA was extracted from gastric biopsies of thirty-four cases of gastric cancer (11 intestinal-type, 23 diffuse-type), and thirty-four of patients with endoscopic gastritis. The presence of cagPAI genes (cagA, cagA promoter, cagE, cagM, tnpB, tnpA, cagT and the left end of the cagII (LEC)) and babA were analyzed by PCR.
Results:
Comparison of H. pylori isolates from gastric cancer and gastritis patients showed significant associations of tnpA and LEC with gastric cancer (73.5% [OR, 6.66; 95% CI, 2.30-19.25] and 58.8% [OR, 10.71; 95% CI, 3.07-37.28] of cases, respectively). Other cagPAI genes were detected in both groups at similar frequencies.
Conclusions:
tnpA and LEC of H. pylori cagPAI were associated with gastric cancer; nonetheless, these results were restricted within this group of patients and further studies are needed to confirm these results in a larger sample and determine their role in gastric carcinogenesis.</description>
        <link>http://www.infectagentscancer.com/content/5/1/1</link>
                <dc:creator>Rejane Mattar</dc:creator>
                <dc:creator>Maria Monteiro</dc:creator>
                <dc:creator>Sergio Marques</dc:creator>
                <dc:creator>Bruno Zilberstein</dc:creator>
                <dc:creator>Claudio Hashimoto</dc:creator>
                <dc:creator>Flair Carrilho</dc:creator>
                <dc:source>Infectious Agents and Cancer 2010, 5:1</dc:source>
        <dc:date>2010-01-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-5-1</dc:identifier>
        <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-01-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/4/1/14">
        <title>The seroprevalence of human papillomavirus by immune status and by ethnicity in London</title>
        <description>Background:
The natural history of cutaneous HPV is unclear and in particular, seroprevalence among individuals with different levels of immune function and ethnicity is unknown. As part of a study of cutaneous squamous cell carcinoma (SCC) and HPV among organ transplant recipients (OTR) from London, we investigated the seroprevalence and risk factors for 34 HPV types (detected using Luminex technology) among 409 OTR patients without skin cancer (243 Caucasians and 166 non-Caucasians), 367 individuals with end stage renal failure on dialysis (222 Caucasians and 145 non-Caucasians) and 152 immunocompetent (IC) individuals without skin cancer (102 Caucasians and 50 non-Caucasians) to compare the HPV seroprevalence in patients with differing immune status and ethnicity. In total, seroprevalence data from 928 individuals, all from London, was available.
Results:
Overall, no difference between HPV seroprevalence by immune status was observed (P = 0.3) among Caucasian or among non-Caucasian individuals, with seroprevalence varying from 87% to 94% across different immune status and ethnic groups. Those individuals seropositive to multiple types of one genus were more likely to be seroreactive to multiple types of another genus, independent of immune status or ethnicity. Lower seroprevalence for gammaHPV 4, and to a lesser extent gammaHPV 48, were observed among OTR compared to IC and dialysis patients. Higher seroprevalence against antibodies to betaHPV 93 were detected more frequently in non-Caucasians than Caucasians whereas muHPV 1 and, to a lesser extent, gammaHPV 4 were found more frequently among Caucasians - these findings were independent of immune status. Within non-Caucasian subgroups, the seroprevalence of 8 HPV (alpha-mucosal HPV16 and 13, alpha-cutaneous HPV7 and 2, betaHPV8, 17, 23 and 38) was significantly (P &lt; 0.02) higher in Black compared to Asian patients. HPV16 being sexually transmitted, this might suggest a potential sexual route of transmission for some beta HPV types.
Conclusion:
We did not observe major disturbance in antibody response between immunocompetent, dialysis and OTR individuals, but significant differences in HPV seroprevalence were identified according to ethnicity. Further research is needed to clarify the natural history of cutaneous HPV, particularly given the growing research interest in its possible role in the pathogenesis of cutaneous SCC.</description>
        <link>http://www.infectagentscancer.com/content/4/1/14</link>
                <dc:creator>Delphine Casabonne</dc:creator>
                <dc:creator>Tim Waterboer</dc:creator>
                <dc:creator>Kristina Michael</dc:creator>
                <dc:creator>Michael Pawlita</dc:creator>
                <dc:creator>Lisa Mitchell</dc:creator>
                <dc:creator>Robert Newton</dc:creator>
                <dc:creator>Catherine Harwood</dc:creator>
                <dc:creator>Charlotte Proby</dc:creator>
                <dc:source>Infectious Agents and Cancer 2009, 4:14</dc:source>
        <dc:date>2009-09-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-4-14</dc:identifier>
        <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2009-09-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/4/1/13">
        <title>The seroepidemiology of human papillomavirus among Caucasian transplant recipients in the UK</title>
        <description>Background:
Despite intensive study of high-risk mucosal human papillomaviruses (HPV), little is known of the epidemiology of cutaneous HPV. As part of a study of cutaneous squamous cell carcinoma and HPV among organ transplant recipients (OTR) from London and Oxford, we investigated the seroprevalence and risk factors for 34 HPV types (detected using Luminex technology) among 425 Caucasian OTR without skin cancer.
Results:
Overall, 86% of participants were seropositive to at least one HPV: 41% to mucosal alpha types, 33% to cutaneous alpha types, 57% to alpha types, 56% to beta, 47% to gamma types and 45% to other types (nu, mu, HPV101 and 103). In both centres, the most common types were HPV6 (33% and 26% for London and Oxford respectively), HPV8 (24% and 18%), HPV15 (26% and 29%), HPV17 (25% and 21%), HPV38 (23% and 21%), HPV49 (19% and 21%), HPV4 (27% and 23%), HPV65 (30% and 25%), HPV95 (22% and 20%), HPV1 (33% and 24%) and HPV63 (28% and 17%). The seroprevalence of 8 HPV types differed significantly (P &lt; 0.05) between London and Oxford. Those individuals seropositive to multiple types of one genus were more likely to be seroreactive to multiple types of another genus. As expected, antibodies against mucosal alphaHPV types were more frequent in younger patients and among women. Sunbed use and sunbathing was associated with seropositivity to multiple gammaHPV (P-trend = 0.007) and self-history of abnormal smear was related to seroactivity to multiple betaHPV (P = 0.01). Skin type and other self reported markers of exposure to ultraviolet radiation were not consistently associated with any HPV types. No other distinguishing epidemiological features of transplant recipients with antibodies against single or multiple HPV types were identified.
Conclusion:
Findings for mucosal HPV types were in line with results from previous studies. We observed differences in HPV seroprevalence between organ transplant recipients from two geographically close centres but no clear risk factor was found associated with cutaneous HPV seropositivity among organ transplant recipients. These findings have implications for interpretation of future seroepidemiology studies addressing the association between HPV and cutaneous SCC in OTR populations.</description>
        <link>http://www.infectagentscancer.com/content/4/1/13</link>
                <dc:creator>Delphine Casabonne</dc:creator>
                <dc:creator>Tim Waterboer</dc:creator>
                <dc:creator>Kristina Michael</dc:creator>
                <dc:creator>Michael Pawlita</dc:creator>
                <dc:creator>Aoife Lally</dc:creator>
                <dc:creator>Liza Mitchell</dc:creator>
                <dc:creator>Beata Imko-Walczuk</dc:creator>
                <dc:creator>Fenella Wojnarowska</dc:creator>
                <dc:creator>Robert Newton</dc:creator>
                <dc:creator>Charlotte Proby</dc:creator>
                <dc:creator>Catherine Harwood</dc:creator>
                <dc:source>Infectious Agents and Cancer 2009, 4:13</dc:source>
        <dc:date>2009-09-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-4-13</dc:identifier>
        <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2009-09-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
